Intact Investment Management Inc. Buys 2,520 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Intact Investment Management Inc. increased its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 79.2% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 5,700 shares of the medical research company’s stock after acquiring an additional 2,520 shares during the quarter. Intact Investment Management Inc.’s holdings in IQVIA were worth $1,120,000 at the end of the most recent quarter.

Other large investors have also bought and sold shares of the company. Impax Asset Management Group plc increased its position in IQVIA by 9.7% in the 3rd quarter. Impax Asset Management Group plc now owns 1,793,010 shares of the medical research company’s stock valued at $423,885,000 after buying an additional 157,809 shares in the last quarter. Assetmark Inc. increased its holdings in shares of IQVIA by 612.5% during the third quarter. Assetmark Inc. now owns 228 shares of the medical research company’s stock valued at $54,000 after acquiring an additional 196 shares in the last quarter. Covestor Ltd raised its position in shares of IQVIA by 34.4% during the third quarter. Covestor Ltd now owns 246 shares of the medical research company’s stock worth $59,000 after purchasing an additional 63 shares during the period. Apollon Wealth Management LLC lifted its holdings in shares of IQVIA by 9.6% in the 3rd quarter. Apollon Wealth Management LLC now owns 4,874 shares of the medical research company’s stock worth $1,155,000 after purchasing an additional 427 shares in the last quarter. Finally, GSA Capital Partners LLP acquired a new stake in IQVIA in the 3rd quarter valued at $230,000. 89.62% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

IQV has been the topic of a number of recent research reports. Citigroup dropped their price objective on shares of IQVIA from $225.00 to $210.00 and set a “neutral” rating on the stock in a research note on Tuesday, March 4th. Robert W. Baird dropped their price target on shares of IQVIA from $212.00 to $210.00 and set a “neutral” rating on the stock in a research report on Tuesday, January 21st. UBS Group decreased their price objective on IQVIA from $260.00 to $255.00 and set a “buy” rating for the company in a report on Friday, February 7th. JPMorgan Chase & Co. dropped their target price on IQVIA from $240.00 to $232.00 and set an “overweight” rating on the stock in a report on Tuesday, February 18th. Finally, Truist Financial reissued a “buy” rating and issued a $263.00 price target (up from $261.00) on shares of IQVIA in a research report on Monday, February 10th. Five research analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $249.05.

IQVIA Price Performance

Shares of NYSE:IQV opened at $185.40 on Friday. The company has a 50-day moving average price of $196.63 and a two-hundred day moving average price of $210.95. IQVIA Holdings Inc. has a twelve month low of $179.28 and a twelve month high of $256.34. The company has a quick ratio of 0.84, a current ratio of 0.84 and a debt-to-equity ratio of 2.12. The firm has a market capitalization of $32.69 billion, a PE ratio of 24.72, a P/E/G ratio of 1.99 and a beta of 1.50.

IQVIA (NYSE:IQV) last issued its earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. Equities analysts forecast that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.